Track the CENTENE CORP stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, CENTENE CORP has recorded 391 public disclosures. Market capitalisation: €32.3bn. The latest transaction was disclosed on 27 August 2026 (Cession). Among the most active insiders: Burdick Kenneth A. All data is free.
Analysts rate CENTENE CORP Buy (bullish), based on 18 analysts. Average price target: US$71.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
25 of 391 declarations
Centene Corp. (ticker: CNC) is a major U.S. managed healthcare company listed on the NYSE in the United States, with headquarters in St. Louis, Missouri. The company was founded in 1984 as a nonprofit Medicaid plan under the name Family Hospital Physician Associates (FHPA) in Milwaukee, then adopted the Centene name in 1997 and relocated its corporate headquarters to St. Louis. Over time, Centene has evolved from a local safety-net insurer into a national managed-care platform built around a community-based operating model. ([centene.com](https://www.centene.com/who-we-are/history.html?utm_source=openai)) Centene’s core business is organized around three main lines: Medicaid, Medicare, and the Health Insurance Marketplace. It also reports an “Other” segment for residual activities, although management has signaled a sharper strategic focus on its core platforms. The company describes itself as the largest Medicaid managed care organization in the U.S. and a long-standing leader in the Marketplace. Its product set includes government-sponsored health plans, Medicare Advantage coverage, Medicare Prescription Drug Plans (PDP), and related care-management and health-services solutions. ([centene.com](https://www.centene.com/who-we-are/history.html?utm_source=openai)) From a competitive standpoint, Centene’s scale and local-market approach are central differentiators. The company operates across all 50 states and states that it serves more than one in 15 people nationwide. Its business model is highly regulated and operationally complex, but it benefits from a large membership base and a diversified footprint across state Medicaid programs and ACA Marketplace plans. Recent disclosures, however, highlight a more challenging operating backdrop, particularly in Medicaid and Marketplace, with margin pressure and ongoing portfolio cleanup. ([centene.com](https://www.centene.com/who-we-are/history.html?utm_source=openai)) Recent developments are important for investors. On February 6, 2026, Centene reported full-year 2025 results and announced 2026 guidance, including adjusted diluted EPS guidance above $3.00, while emphasizing actions aimed at restoring Marketplace profitability and stabilizing the Medicaid trajectory. In December 2025, the company also signed a definitive agreement to divest the remaining Magellan Health businesses, underscoring a broader strategic simplification effort. In its first-quarter 2026 update, Centene continued to focus on margin improvement, cost discipline, and execution across its core segments. ([investors.centene.com](https://investors.centene.com/2026-02-06-CENTENE-CORPORATION-REPORTS-2025-RESULTS-AND-ANNOUNCES-2026-GUIDANCE?utm_source=openai)) For French-speaking investors, Centene is best viewed as a managed-care and government-program healthcare operator with strong U.S. scale, a defensive end-market profile, and meaningful sensitivity to reimbursement trends, utilization patterns, and regulatory changes in Medicaid and the ACA Marketplace. ([centene.com](https://www.centene.com/content/dam/centenedotcom/investor_docs/CNC-2026-Proxy-2025-Annual-Report.pdf?utm_source=openai))